Legal Representation
Attorney
Julie L. Dalke
USPTO Deadlines
Application History
27 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 30, 2012 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 30, 2012 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 19, 2012 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 18, 2012 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 18, 2012 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Dec 15, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 15, 2011 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jun 14, 2011 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 10, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 10, 2011 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 10, 2011 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 28, 2010 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 2, 2010 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 2, 2010 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 27, 2010 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Sep 27, 2010 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Sep 17, 2010 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 15, 2010 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 15, 2010 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 15, 2010 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 21, 2010 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 21, 2010 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 21, 2010 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 14, 2010 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 15, 2010 | MPMK | O | NOTICE OF PSEUDO MARK MAILED | Loading... |
| Apr 14, 2010 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 13, 2010 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations for the treatment of Tangiers disease, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), cystic fibrosis, human immunodeficiency virus (HIV), diabetes, hyperlipidemia, cancer, atherosclerosis, hypertension, insulin resistance, dyslipidemia, and hepatic cholestasis; pharmaceutical preparations for the treatment of the metabolic system, the central nervous system, the peripheral nervous system, the liver, the immune system, the renal system, and the cardiovascular system; pharmaceutical preparations for the treatment of metabolic diseases and disorders, infectious diseases, autoimmune diseases and disorders, inflammatory disorders, and cardiovascular disease; pharmaceutical preparations for the treatment of renal diseases, disorders and dysfunction; pharmaceutical preparations for the prevention and treatment of organ rejection; pharmaceutical preparations for use in tissue and organ transplantation, for adjuvant use in tissue and organ transplantation, for use in oncology, and for use in chemotherapy; pharmaceutical preparations and substances for the treatment of viral related diseases and disorders, and immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of pain; pharmaceuticals, namely, anti-infectives, immunosuppressants, anti-inflamatories, and antivirals; analgesic pharmaceutical preparations; anti-diabetic pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
LIMERICK BIOLOGICAL PHARMACEUTICAL
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"BIOPHARMA"